Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Celgene Corporation    CELG

CELGENE CORPORATION (CELG)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Celgene : to Announce Third Quarter 2017 Results on October 26, 2017; Will Host an Investor Webcast Event from the MSParis2017-7th Joint ECTRIMS - ACTRIMS Meeting on October 28, 2017

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/02/2017 | 01:35pm CEST

SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ: CELG) will host a conference call and live audio webcast on Thursday, October 26, 2017 at 9 a.m. ET to discuss third quarter 2017 financial and operational results. The webcast can be accessed from the Investor Relations page at www.celgene.com.

Celgene will alsohost a webcast of an investor event at the MSParis2017-7th Joint European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) - American Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Meeting on Saturday, October 28 at 6:00 p.m. CEST (12:00 p.m. ET). Members of Celgene's management team and clinical investigators will discuss the data presentations at the ECTRIMS Meeting. The event will be webcast live and will be available in the Investor Relations section of the Company's web site at www.celgene.com.

About Celgene

Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through next-generation solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. For more information, please visit www.celgene.com. Follow Celgene on Social Media: @Celgene, Pinterest, LinkedIn, Facebook and YouTube.

Forward-Looking Statements

This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words 'expects,' 'anticipates,' 'believes,' 'intends,' 'estimates,' 'plans,' 'will,' 'outlook' and similar expressions. Forward-looking statements are based on management's current plans, estimates, assumptions and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact of a number of factors, many of which are discussed in more detail in our Annual Report on Form 10-K and our other reports filed with the Securities and Exchange Commission.

Hyperlinks are provided as a convenience and for informational purposes only. Celgene bears no responsibility for the security or content of external websites.

View source version on businesswire.com : http://www.businesswire.com/news/home/20171002005698/en/

Celgene Corporation
Patrick E. Flanigan III, 908-673-9969
Corporate VP, Investor Relations
orBrian Gill, 908-673-9530
VP, Corporate Communications

Source: Celgene Corporation

News Provided by Acquire Media

Celgene Corporation published this content on 02 October 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 02 October 2017 11:34:06 UTC.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CELGENE CORPORATION
07/12CELGENE : and Acceleron Announce Luspatercept Achieved Primary and Key Secondary..
AQ
07/12CELGENE CORPORATION : - Anti-PD-L1 Immunotherapy Plus ABRAXANE Significantly Red..
AQ
07/11CELGENE : and Acceleron Announce Luspatercept Achieved Primary and All Key Secon..
AQ
07/11TODAY'S RESEARCH REPORTS ON TRENDING : Galapagos and Celgene
AC
07/11CELGENE : and Acceleron Announce Luspatercept Achieved Primary and All Key Secon..
AQ
07/11ACCELERON PHARMA : Latest luspatercept readout a second win for Acceleron, Celge..
AQ
07/10CELGENE : Health Care Shares Move Higher as Focus Shifts to Earnings -- Health C..
DJ
07/10CELGENE : Anti-PD-L1 Immunotherapy Plus ABRAXANE® Significantly Reduced the Risk..
BU
07/10CELGENE : Golumbeski resurfaces, at Grail
AQ
07/09CELGENE CORP /DE/ : Other Events (form 8-K)
AQ
More news
News from SeekingAlpha
11:10aBig Pharma in the red on ramped up pressure on drug prices 
07/18FDA committed to easing approval path for biosimilars 
07/18You Can't Go Wrong Buying Netflix On Dips - Cramer's Mad Money (7/17/18) 
07/16CVS responds to Trump Administration's request for info on now to lower drug .. 
07/16The Smart Way To Find Undervalued Stocks 
Financials ($)
Sales 2018 14 919 M
EBIT 2018 8 448 M
Net income 2018 4 834 M
Debt 2018 11 631 M
Yield 2018 -
P/E ratio 2018 13,46
P/E ratio 2019 10,59
EV / Sales 2018 4,95x
EV / Sales 2019 4,05x
Capitalization 62 226 M
Chart CELGENE CORPORATION
Duration : Period :
Celgene Corporation Technical Analysis Chart | CELG | US1510201049 | 4-Traders
Technical analysis trends CELGENE CORPORATION
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 113 $
Spread / Average Target 31%
EPS Revisions
Managers
NameTitle
Mark J. Alles Chairman, President, CEO & COO
Peter N. Kellogg Executive VP, Chief Financial & Accounting Officer
Joseph S. Camardo Senior Vice President-Global Medical Affairs
Jay T. Backstrom Chief Medical Officer
Rupert J. Vessey President-Research & Early Development
Sector and Competitors
1st jan.Capitalization (M$)
CELGENE CORPORATION-17.80%62 226
JOHNSON & JOHNSON-7.59%346 292
PFIZER3.95%220 236
ROCHE HOLDING LTD.-4.77%200 995
NOVARTIS-2.11%200 139
MERCK AND COMPANY11.85%168 225